Last updated: 2026-09-16 12:18:20. Prices reflect the latest pre-market trading data. Stock price data is sourced from Massive.
Zentalis Pharmaceuticals, Inc. (ZNTL) operates in the PHARMACEUTICAL PREPARATIONS sector and is listed on NASDAQ. The stock is currently priced at $3.22, with a market capitalisation of $331.35M and a P/E ratio of --. Over the past 52 weeks, its price has ranged from $1.21 to $6.95. This page covers its latest market performance, valuation, price trends and company information.
$331.35M | |
$3.20 | |
$87.19 | |
$1.01 | |
$3.13 | |
617.00 | |
1.21M | |
-- | |
$6.95 | |
$1.21 | |
-- | |
-- |
Zentalis Pharmaceuticals, Inc. (ZNTL) is trading at $3.22 in pre-market trading as of 2026-09-16 12:14:00, up 2.88% ($0.09) from the previous close of $3.13
Pre-market trading shows how investors are pricing ZNTL before the regular session opens. The current pre-market price is above the previous close, indicating positive early trading sentiment.
Over the past seven days, Zentalis Pharmaceuticals, Inc. (ZNTL) moved from $3.99 to $3.22, representing a decline of 19.30% ($0.77).
The stock traded between $3.12 and $4.19 during the period. The latest price is near the lower end of the 7-day range, indicating strong downward.
The average daily volume was 871.88 thousand shares, up versus the previous seven-day period, indicating higher trading activity.
Position in Range: 35.0%
ZNTL is currently trading at $3.22, placing it 35.0% of the way from its 52-week low of $1.21 to its 52-week high of $6.95. This percentage reflects the stock's relative position within its 52-week trading range, not its valuation or future performance.
Zentalis Pharmaceuticals Inc is a clinical-stage biopharmaceutical company developing azenosertib (ZN-c3), a potentially first-in-class and best-in-class WEE1 inhibitor for patients with Cyclin E1-positive platinum-resistant ovarian cancer (Cyclin E1+ PROC). The Company manages its operations as a single segment for the purposes of assessing performance and making operating decisions.
| Industry | PHARMACEUTICAL PREPARATIONS |
| Employees | 106 |
| Exchange | NASDAQ |
| Company Website |
Eligible investors can buy real shares of Zentalis Pharmaceuticals, Inc. (ZNTL) through MEXC RealStocks. Follow these three steps to open a RealStocks account, transfer USDT, and place a US stock order.